As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

For now, the group is sticking with what it knows ahead of a big year in lymphoma.

The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.

The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.